HelixBind is pioneering a diagnostic platform specifically designed to address bloodstream infections, which are critical in the context of sepsis—a major global health crisis. The company’s proprietary technology enables rapid and accurate identification of pathogens, delivering results within approximately four hours, significantly faster than traditional blood culture tests that can take 2-3 days. This innovative approach allows clinicians to make timely and informed decisions regarding antimicrobial treatments, ultimately improving patient outcomes and reducing the risk of antimicrobial resistance. HelixBind's tests are capable of identifying over 20 different pathogens with high sensitivity, even from small blood samples, which is crucial given the complexity of blood as a clinical specimen.

The technology employed by HelixBind incorporates multiple patented methods that enhance the detection and characterization of microorganisms in blood samples. By utilizing artificial nucleic acids instead of traditional DNA, HelixBind's tests can provide detailed species-level identification and assess markers of antimicrobial resistance. The entire testing process is streamlined into a user-friendly disposable cassette, which automates sample handling and minimizes contamination risks. This design not only simplifies the testing procedure for healthcare providers but also ensures that critical diagnostic information is readily available and easily integrated with hospital laboratory information systems (LIS), facilitating better clinical decision-making.

United States

HelixBind is working to revolutionize care for invasive infections such as sepsis. Our novel diagnostic platform provides faster, more accurate, and more informative microbiology results direct from blood, assisting clinicians in identifying bloodstream infections and developing personalized antimicrobial interventions..

Our approach can improve outcomes, save lives, and reduce the spread of antimicrobial resistance.

HelixBind

Company Details